Short bowel syndrome and intestinal failure
Clinical research in short bowel syndrome focuses on patients with intestinal failure, including studies assessing long-term treatment use, efficacy, and safety in this gastrointestinal disorder. The portfolio also includes work in SBS-IF populations.
- Short bowel syndrome
- Intestinal failure
- Gastrointestinal disease management
- Long-term treatment safety
Research activity in this area centers on therapies aimed at improving intestinal function and supporting chronic management of malabsorption-related disease.
Obesity and body weight control
Trials in weight management and weight reduction evaluate treatment approaches for obesity and overweight with associated comorbidities, with attention to body weight outcomes and adjunctive lifestyle measures.
- Obesity
- Overweight with comorbidities
- Weight reduction
- Body weight regulation
The sponsor’s interest extends to metabolic interventions that address excess body weight and related cardiometabolic risk.
Congenital hyperinsulinism in children
Paediatric studies address congenital hyperinsulinism in children, with emphasis on the safety and continued use of treatment in a rare endocrine disorder that requires careful glucose control.
- Congenital hyperinsulinism
- Paediatric endocrinology
- Glucose regulation
- Rare childhood disease
This area reflects a therapeutic focus on metabolic disorders in childhood, particularly conditions involving abnormal insulin secretion.
Pharmacokinetics and special populations
Several studies examine pharmacokinetics, safety, and tolerability in healthy volunteers and in people with hepatic impairment, renal impairment, or other physiological differences affecting drug handling.
- Pharmacokinetics
- Hepatic impairment
- Renal impairment
- Healthy volunteers
These investigations support understanding of how investigational therapies behave across varied clinical and metabolic settings.
Autoimmune diseases
The sponsor also funds research in autoimmune diseases, indicating interest in immune-mediated conditions alongside its metabolic and gastrointestinal programs.
- Autoimmune disease
- Immune-mediated disorders
- Chronic inflammatory disease
This adds an immunology-focused component to the broader therapeutic portfolio.
